Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05223660
Other study ID # KT07-US-03
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 7, 2022
Est. completion date September 6, 2022

Study information

Verified date October 2022
Source Yiling Pharmaceutical Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1 single-center study to assess the pharmacokinetics (PK), safety and tolerability of KT07 capsules in healthy adult subjects. This study consists of 2 parts: Part 1 and Part 2. The primary objectives of Part 1 include selection of suitable PK markers for bioanalysis, development and validation of GLP bioanalytical methods for follow-up PK studies, assessment of PK of potential markers following an oral administration of KT07, and provision of PK sampling strategy for Part 2. The primary objective of Part 2 is to evaluate the PK profile following a single dose and multiple doses in healthy adult subjects.


Description:

This is a 2-part PK study. Each Part consists of 3 phases: a 2-week screening phase, drug administration and PK sampling phase, then a safety follow-up visit at Day 7 after the last dose. Subjects enter screening at Visit 1. Part 1: Pilot single-dose PK Study Part 1 is an open-label study. Six (6) eligible male adult healthy volunteers aged between 18 to 65 years will receive a single oral dose of KT07 capsules on Day 1. Part 2: Single and multiple-dose PK Study A total of 20 healthy subjects will participate in this part of the study, which consists of 2 cohorts with 10 subjects each. Subjects will receive either active treatment or placebo treatment in each cohort in a double-blind manner to evaluate PK and safety of KT07.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date September 6, 2022
Est. primary completion date July 20, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Subject voluntarily has agreed to participate in this study and signed an Institutional Review Board (IRB)-approved informed consent before any of the screening procedures will be performed. 2. 18 to 65 years of age, inclusive, at screening, male or female. 3. Body mass index (BMI) between 17.5 and 32.0 kg/m2 at screening. 4. Healthy, determined by pre-study medical evaluation and Investigator/designee discretion (medical history, physical examination, vital signs, ECG, and clinical laboratory evaluations). 5. All female subjects of child-bearing potential must have a negative serum pregnancy test result. All female subjects of child-bearing potential and male subjects and their spouse/partner must agree to use a medically acceptable method of contraception (e.g, abstinence, an intrauterine device, a double barrier method such as condom + spermicide or condom + diaphragm with spermicide, a contraceptive implant, an oral contraceptive or have a vasectomized partner with confirmed azoospermia) throughout the entire study period, and for 90 days after study drug discontinuation. 6. Agrees to the collection of nasopharyngeal (NP) swabs for SARS-CoV-2 testing. Exclusion Criteria: 1. Clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s) as determined by the Investigator/designee. 2. Any disorder that would interfere with the absorption, distribution, metabolism, or excretion of drugs. 3. Any concurrent disease or condition that, in the opinion of the Investigator/designee, would make the subject unsuitable for participation in the clinical study. 4. Subject has history of alcohol and/or illicit drug abuse within one year of the Screening visit. 5. Positive SARS-CoV-2 testing by standard RT-PCR assay. 6. Positive Screening test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, or human immunodeficiency virus (HIV) antibody. 7. Positive urine test for ethanol/drug/cotinine at Screening or Day -1. 8. History of alcohol abuse as judged by the Investigator within approximately 1 year. Average weekly alcohol intake > 21 units/week or are unwilling to avoid use of alcohol or alcohol-containing foods, medications or beverages, within 48 hours prior to Day -1 until completion of the study. Positive alcohol test at Screening. (One unit of alcohol equals about 250 mL of beer or lager, 100 mL of wine, or 35 mL of spirits). 9. History of illicit drug abuse, within approximately 1 year or evidence of current use as judged by the Investigator or are unwilling to abstain from illicit drug use consumption during the entire study. Positive drug test, including marijuana. 10. Excessive consumption of coffee, tea, cola, or other caffeinated beverages; excessive consumption is defined as >6 servings per day (1 serving contains approximately 120 mg caffeine). 11. Donation of blood (> 500 mL) or blood products within 2 months prior to Day -1. 12. Use of over-the-counter (OTC) vitamins and medications, prescription medications, an investigational drug or herbal remedies from 14 days prior to the first dose. 13. Subject has a history of hypersensitivity to the investigational product (IP) or any of the ingredient or excipient of IP. 14. Subjects who took a monoamine oxidase inhibitor (MAOI) within 2 weeks prior to admission. 15. Subject has consumed grapefruit or grapefruit juice within the 14 days prior to admission. 16. Pregnant or breast-feeding female subjects 17. Previous history of difficulty swallowing capsules. 18. History and/or family history of congenital long QT syndrome, unexplained syncope, or other additional risks of Torsade de Pointes or sudden premature death. 19. Subject with any of the following ECG results at Screening or Admission will be excluded: 1. PR interval >220 msec or <110 msec 2. RR interval > 1333 msec 3. QRS interval >120 msec 4. QTcF >470 msec 5. ST segment elevation or depression considered clinically significant by the PI or designee 6. T-wave abnormalities considered to be clinically significant by the PI or designee 20. An average systolic blood pressure =140 mmHg or = 90 mmHg; an average diastolic blood pressure = 90 mmHg or = 50 mmHg. 21. Participants with history of hyperthyroidism and increased intraocular pressure. 22. Glomerular filtration rate (GFR) =70 mL/min/1.73 m2, as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.at Screening 23. Ongoing liver disease or unexplained liver function test (LFT) elevations, defined as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase (GGT), or alkaline phosphatase (ALP) >1.2 × upper limit of the reference range (ULRR) at Screening or Admission 24. History of significant multiple and/or severe allergies (including latex allergy); anaphylactic reaction; or significant prescription drug, non-prescription drug, or food intolerance. 25. Any vaccination within 7 days of Screening or any vaccination with an mRNA or adenovirus platform vaccine within 30 days of Screening 26. Hemoglobin (HbA1C) > 6.5 27. Any other factors that the Investigator considers not suitable for participating in this trial. 28. Subject is unable to understand the protocol requirements, instructions and study related restrictions, as well as the nature, scope, and possible consequences of the clinical study. 29. Subject is unlikely to comply with the protocol requirements, instructions and study related restrictions, such as uncooperative attitude, inability to return for follow-up visits, and improbability of completing the clinical study.

Study Design


Intervention

Drug:
Low dose KT07
A single dose of 4 capsules, followed by multiple doses on Days 8-12
High dose KT07
A single dose of 6 capsules, followed by multiple doses on Days 8-12
Low dose Placebo
A single dose of 4 capsules, followed by multiple doses on Days 8-12
High dose Placebo
A single dose of 6 capsules, followed by multiple doses on Days 8-12

Locations

Country Name City State
United States Pharmaron Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Yiling Pharmaceutical Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the curve (AUC) 0-t AUC calculation up to the last measurable concentration 13 days
Primary AUC0-8 AUC calculation from time 0 to infinity 13 days
Primary Maximum (or peak) serum concentration (Cmax) Assess the peak concentration of KT07 13 days
Primary Time to achieve maximum drug concentration (Tmax) Assess when KT07 reach its peak concentration 13 days
Primary Trough concentration (Ctrough) Assess the lowest concentration of KT07 13 days
Primary Time required to reduce the drug concentration to ½ of its initial value (t1/2) Assess the half-life of KT07 13 days
Primary Volume of plasma cleared of drug per unit time (CL/F) Assess the plasma clearance of KT07 13 days
Primary Volume of distribution at terminal phase (Vz/F) Assess the Volume of distribution of KT07 13 days
Primary AUCextrap Percentage of AUCinf-pred due to extrapolation from Tlast to infinity 13 days
Primary Cmax (Racc_Cmax) Maximum concentrations anticipated at plateau 13 days
Primary AUC (Racc_AUCss) Area under the curve anticipated at plateau 13 days
Primary Accumulation factor Accumulation factor (R) reflects how much drug is accumulated in the body at steady state after multiple dosing as compared to that after single dosing 13 days
Secondary Severity of adverse events Severity assessment of adverse events using protocol-defined criteria after first dose in adult healthy subjects 19 days
Secondary Causality of adverse events Causality assessment of adverse events using protocol-defined criteria after first dose in adult healthy subjects 19 days
Secondary Incidence of adverse events Incidence of adverse events up to 19 days after first dose in adult healthy subjects 19 days
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT00984009 - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1